Detalles de la búsqueda
1.
A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT.
Cancers (Basel)
; 14(12)2022 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35740697
Resultados
1 -
1
de 1
1
Próxima >
>>